Myeloproliferative Neoplasms | Specialty

The OncLive Myeloproliferative Neoplasms condition center is a comprehensive resource for clinical news and expert insights on myeloproliferative neoplasms, including myelofibrosis, polycythemia vera, and essential thrombocythemia. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in myeloproliferative neoplasms.

Ruxolitinib Combo Regimens Emerging in Myelofibrosis

September 17th 2019

Although several newer JAK inhibitors are being investigated, such as pacritinib, momelotinib, and the recently FDA-approved fedratinib, most combinations are being explored in combination with ruxolitinib.

JAK Inhibition Continues to Push Progress in Myelofibrosis

September 13th 2019

Ruben Mesa, MD, discusses the JAKARTA and JAKARTA-2 studies and the implications their data have on the field of myelofibrosis.

Dr. Michaelis on Fedratinib in Myelofibrosis Treatment

September 13th 2019

Laura C. Michaelis, MD, discusses the integration of fedratinib into the treatment sequence of myelofibrosis.

Therapeutic Challenges Continue to Emerge in Myelofibrosis

August 28th 2019

James K. McCloskey II, MD, discussed current treatment options for patients with myelofibrosis as well as further options in development in clinical trials.

Dr. Synder on the Quest to Revolutionize Management of Myelofibrosis

August 28th 2019

David S. Snyder, MD, associate chair, Department of Hematology and Hematopoietic Cell Transplantation, professor, Hematology and Hematopoietic Cell Transplantation, and hematologist/oncologist, City of Hope, discusses ongoing research dedicated to providing more curative options to patients with myelofibrosis.

FDA Approves Fedratinib for Myelofibrosis

August 16th 2019

The FDA has approved fedratinib (Inrebic) for the treatment of adult patients with intermediate-2 or high-risk primary or secondary myelofibrosis.

Symptom Management, Risk Stratification Crucial in MPN Treatment

July 10th 2019

James M. Rossetti, DO, discusses strategies for symptom management, tools available for risk stratification, and updated data with some of the pivotal agents in myeloproliferative neoplasms.

Unmet Needs and Future Directions in Treating MPNs

July 9th 2019

Other Pathways Studied for MF

July 9th 2019

Emerging Agents Pacritinib and Momelotinib for MF

July 9th 2019

Fedratinib in MF: JAKARTA2 and FREEDOM Trials

July 9th 2019

Dosing of Ruxolitinib in PV and MF

July 9th 2019

COMFORT Ruxolitinib Studies for Myelofibrosis

July 9th 2019

Ruxolitinib's Role in Treating Myelofibrosis

July 9th 2019

Diagnosis and Risk Stratification in Myelofibrosis

July 9th 2019

Interferon's Role in Treating Polycythemia Vera

July 9th 2019

RESPONSE-2 Trial: Ruxolitinib for PV

July 9th 2019

Ruxolitinib for Treatment of Polycythemia Vera

July 9th 2019

Cytoreductive Therapy in Polycythemia Vera

July 9th 2019

Treating Leukocytosis in Polycythemia Vera

July 9th 2019